Comments

10x Genomics Analyst Ratings

TXGNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$15.76

0.301.94%

At close: Dec 15, 4:00 PM EST

$15.51

-0.25-1.59%

After Hours: 5:20 PM EST

Overview News Earnings Options Guidance

Analyst Ratings

Insider Trades Short Interest Stock Report

Consensus Rating¹

Neutral

Highest Price Target¹

$57.00

Lowest Price Target¹

$6.50

Consensus Price Target¹

$21.53

10x Genomics Analyst Ratings and Price Targets | NASDAQ:TXG | Benzinga

10x Genomics Inc has a consensus price target of $21.53 based on the ratings of 20 analysts. The high is $57 issued by Cowen & Co. on February 16, 2023. The low is $6.5 issued by Goldman Sachs on May 12, 2025. The 3 most-recent analyst ratings were released by Barclays, Citigroup, and Morgan Stanley on December 15, 2025, December 11, 2025, and December 2, 2025, respectively. With an average price target of $20 between Barclays, Citigroup, and Morgan Stanley, there's an implied 28.95% upside for 10x Genomics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast

Jun

Aug

Sep

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.0

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Firms Making Recommendations¹

Barclays

Citigroup

Morgan Stanley

Piper Sandler

Canaccord Genuity

¹calculated from analyst ratings

Analyst Ratings for 10x Genomics

					Get Alert
Dec 15, 2025	41.84%	Luke SergottBarclays 58%	17 22	Previous Overweight Current Overweight	Get Alert
Dec 11, 2025	16.05%	Patrick DonnellyCitigroup 64%	18	Previous Buy Current Neutral	Get Alert
Dec 2, 2025	28.95%	Tejas SavantMorgan Stanley 55%	17 20	Previous Overweight Current Equal-Weight	Get Alert
Nov 11, 2025	22.5%	David WestenbergPiper Sandler 76%	15 19	Previous Neutral Current Neutral	Get Alert
Nov 7, 2025	22.5%	Kyle MiksonCanaccord Genuity 59%	16 19	Previous Buy Current Buy	Get Alert
Nov 7, 2025	-3.29%	Casey WoodringJP Morgan 38%	13 15	Previous Neutral Current Neutral	Get Alert
Nov 7, 2025	-9.74%	Dan LeonardUBS 67%	13 14	Previous Neutral Current Neutral	Get Alert
Nov 7, 2025	9.61%	Luke SergottBarclays 58%	15 17	Previous Overweight Current Overweight	Get Alert
Sep 11, 2025	-3.29%	David WestenbergPiper Sandler 76%	15	Previous Initiates Current Neutral	Get Alert
Aug 12, 2025	9.61%	Tejas SavantMorgan Stanley 55%	17 18	Previous Overweight Current Overweight	Get Alert
Aug 8, 2025	-16.18%	Dan LeonardUBS 67%	12 13	Previous Neutral Current Neutral	Get Alert
Aug 8, 2025	-3.29%	Luke SergottBarclays 58%	13 15	Previous Overweight Current Overweight	Get Alert
Jun 26, 2025	-16.18%	Derik De BruinB of A Securities 76%	12 13	Previous Neutral Current Neutral	Get Alert
Jun 24, 2025	-16.18%	Luke SergottBarclays 58%	12 13	Previous Overweight Current Overweight	Get Alert
May 19, 2025	16.05%	Tejas SavantMorgan Stanley 55%	18 26	Previous Overweight Current Overweight	Get Alert
May 15, 2025	-9.74%	Mason CarricoStephens & Co. 63%	14 14	Previous Overweight Current Overweight	Get Alert
May 13, 2025	-22.63%	Dan LeonardUBS 67%	12 14	Previous Neutral Current Neutral	Get Alert
May 12, 2025	-58.09%	Matthew SykesGoldman Sachs 67%	6.5 7.5	Previous Sell Current Sell	Get Alert
May 12, 2025	-3.29%	Kyle MiksonCanaccord Genuity 59%	15 18	Previous Buy Current Buy	Get Alert
May 9, 2025	-41.97%	Rachel VatnsdalJP Morgan 69%	9 12	Previous Neutral Current Neutral	Get Alert
Apr 10, 2025	-22.63%	Luke SergottBarclays 58%	12 15	Previous Overweight Current Overweight	Get Alert
Mar 4, 2025	-3.29%	Patrick DonnellyCitigroup 64%	15 20	Previous Buy Current Buy	Get Alert
Feb 14, 2025	67.63%	Tejas SavantMorgan Stanley 55%	26 28	Previous Overweight Current Overweight	Get Alert
Feb 14, 2025	-3.29%	Luke SergottBarclays 58%	15 18	Previous Overweight Current Overweight	Get Alert
Feb 13, 2025	16.05%	Kyle MiksonCanaccord Genuity 59%	18 20	Previous Buy Current Buy	Get Alert
Feb 13, 2025	28.95%	Patrick DonnellyCitigroup 64%	20 23	Previous Buy Current Buy	Get Alert
Feb 13, 2025	-22.63%	Rachel VatnsdalJP Morgan 69%	12 14	Previous Neutral Current Neutral	Get Alert
Feb 13, 2025	-9.74%	Dan LeonardUBS 67%	14 20	Previous Neutral Current Neutral	Get Alert
Feb 13, 2025	16.05%	Daniel AriasStifel 80%	18 21	Previous Buy Current Buy	Get Alert
Feb 13, 2025	-22.63%	Mike KratkyLeerink Partners 65%	12 25	Previous Outperform Current Market Perform	Get Alert
Feb 10, 2025	16.05%	Luke SergottBarclays 58%	18 19	Previous Overweight Current Overweight	Get Alert
Jan 13, 2025	80.53%	Tejas SavantMorgan Stanley 55%	28 30	Previous Overweight Current Overweight	Get Alert
Nov 1, 2024	22.5%	Luke SergottBarclays 58%	19 21	Previous Overweight Current Overweight	Get Alert
Oct 30, 2024	48.29%	Patrick DonnellyCitigroup 64%	23 35	Previous Buy Current Buy	Get Alert
Oct 30, 2024	-9.74%	Matthew SykesGoldman Sachs 67%	14 16	Previous Sell Current Sell	Get Alert
Oct 30, 2024	-9.74%	Rachel VatnsdalJP Morgan 69%	14 20	Previous Neutral Current Neutral	Get Alert
Oct 30, 2024	28.95%	Dan LeonardUBS 67%	20 25	Previous Neutral Current Neutral	Get Alert
Oct 15, 2024	35.4%	Luke SergottBarclays 58%	21 24	Previous Overweight Current Overweight	Get Alert
Oct 10, 2024	93.42%	Mason CarricoStephens & Co. 63%	30 30	Previous Overweight Current Overweight	Get Alert
Oct 10, 2024	28.95%	Kyle MiksonCanaccord Genuity 59%	20 32	Previous Buy Current Buy	Get Alert
Sep 4, 2024	93.42%	Mason CarricoStephens & Co. 63%	30 30	Previous Overweight Current Overweight	Get Alert
Sep 3, 2024	125.66%	Mike KratkyLeerink Partners 65%	35	Previous Initiates Current Outperform	Get Alert
Aug 13, 2024	61.19%	Dan LeonardUBS 67%	25 30	Previous Neutral Current Neutral	Get Alert
Aug 13, 2024	196.58%	Tejas SavantMorgan Stanley 55%	46 50	Previous Overweight Current Overweight	Get Alert
Jul 23, 2024	106.32%	Kyle MiksonCanaccord Genuity 59%	32 50	Previous Buy Current Buy	Get Alert
Jul 22, 2024	54.74%	Tycho PetersonJefferies 83%	24 24	Previous Hold Current Buy	Get Alert
Jul 18, 2024	61.19%	Derik De BruinB of A Securities 76%	25 36	Previous Neutral Current Neutral	Get Alert
Jul 18, 2024	28.95%	Rachel VatnsdalJP Morgan 69%	20 40	Previous Overweight Current Neutral	Get Alert
Jul 16, 2024	61.19%	Daniel AriasStifel 80%	25 53	Previous Buy Current Buy	Get Alert
Jul 10, 2024	61.19%	Justin BowersDeutsche Bank 49%	25 55	Previous Buy Current Hold	Get Alert
Jul 9, 2024	3.16%	Matthew SykesGoldman Sachs 67%	16 26	Previous Sell Current Sell	Get Alert
Jun 28, 2024	54.74%	Luke SergottBarclays 58%	24 36	Previous Overweight Current Overweight	Get Alert
Jun 27, 2024	—	Doug SchenkelWolfe Research 72%	—	Previous Outperform Current Peer Perform	Get Alert
Jun 26, 2024	—	Subbu NambiGuggenheim 73%	—	Previous Buy Current Neutral	Get Alert
Jun 25, 2024	—	Subbu NambiGuggenheim 73%	—	Previous Buy Current Neutral	Get Alert
Jun 3, 2024	54.74%	Tycho PetersonJefferies 83%	24	Previous Initiates Current Hold	Get Alert
May 1, 2024	93.42%	Dan LeonardUBS 67%	30 52	Previous Neutral Current Neutral	Get Alert
May 1, 2024	132.11%	Derik De BruinB of A Securities 76%	36 45	Previous Neutral Current Neutral	Get Alert
May 1, 2024	67.63%	Matthew SykesGoldman Sachs 67%	26 30	Previous Sell Current Sell	Get Alert
May 1, 2024	106.32%	Dan BrennanTD Cowen 70%	32 57	Previous Buy Current Hold	Get Alert
May 1, 2024	241.72%	Daniel AriasStifel 80%	53 63	Previous Buy Current Buy	Get Alert
Apr 29, 2024	222.37%	Kyle MiksonCanaccord Genuity 59%	50 65	Previous Buy Current Buy	Get Alert
Apr 18, 2024	254.61%	Justin BowersDeutsche Bank 49%	55 60	Previous Buy Current Buy	Get Alert
Apr 10, 2024	190.14%	Luke SergottBarclays 58%	45 55	Previous Overweight Current Overweight	Get Alert
Feb 16, 2024	306.19%	Daniel AriasStifel 80%	63 68	Previous Buy Current Buy	Get Alert
Jan 25, 2024	254.61%	Luke SergottBarclays 58%	45 55	Previous Overweight Current Overweight	Get Alert
Dec 14, 2023	286.85%	Subbu NambiGuggenheim 73%	60	Previous Initiates Current Buy	Get Alert
Dec 13, 2023	—	Doug SchenkelWolfe Research 72%	—	Previous Initiates Current Outperform	Get Alert
Dec 12, 2023	248.16%	Derik De BruinB of A Securities 76%	36 54	Previous Underperform Current Neutral	Get Alert
Sep 29, 2023	203.03%	Luke SergottBarclays 58%	47 66	Previous Overweight Current Overweight	Get Alert
Sep 19, 2023	351.32%	Kyle MiksonCanaccord Genuity 59%	70	Previous Buy Current Buy	Get Alert
Aug 7, 2023	319.08%	Tejas SavantMorgan Stanley 55%	65 65	Previous Overweight Current Overweight	Get Alert
Aug 4, 2023	325.53%	Luke SergottBarclays 58%	65 66	Previous Overweight Current Overweight	Get Alert
Aug 4, 2023	383.56%	Patrick DonnellyCitigroup 64%	65 75	Previous Buy Current Buy	Get Alert
Jul 13, 2023	93.42%	Matthew SykesGoldman Sachs 67%	25 30	Previous Sell Current Sell	Get Alert
May 18, 2023	319.08%	Mason CarricoStephens & Co. 63%	65	Previous Overweight Current Overweight	Get Alert
May 10, 2023	319.08%	Luke SergottBarclays 58%	65	Previous Initiates Current Overweight	Get Alert
May 4, 2023	338.43%	Daniel AriasStifel 80%	57 68	Previous Current Buy	Get Alert
May 4, 2023	325.53%	Dan BrennanTD Cowen 70%	62 66	Previous Current Outperform	Get Alert
May 4, 2023	319.08%	Kyle MiksonCanaccord Genuity 59%	58 65	Previous Current Buy	Get Alert
May 4, 2023	319.08%	Mason CarricoStephens & Co. 63%	65	Previous Current Overweight	Get Alert
Mar 31, 2023	319.08%	Mason CarricoStephens & Co. 63%	65	Previous Initiates Current Overweight	Get Alert
Feb 16, 2023	319.08%	Tejas SavantMorgan Stanley 55%	64 65	Previous Current Overweight	Get Alert
Feb 16, 2023	273.95%	Kyle MiksonCanaccord Genuity 59%	55 58	Previous Current Buy	Get Alert
Feb 16, 2023	267.5%	Dan BrennanCowen & Co. 70%	52 57	Previous Current Outperform	Get Alert
Feb 2, 2023	222.37%	John SourbeerUBS 37%	50	Previous Initiates Current Neutral	Get Alert

FAQ

What is the target price for 10x Genomics (TXG) stock?

The latest price target for 10x Genomics (NASDAQ:TXG) was reported by Barclays on December 15, 2025. The analyst firm set a price target for $22.00 expecting TXG to rise to within 12 months (a possible 41.84% upside). 32 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for 10x Genomics (TXG)?

The latest analyst rating for 10x Genomics (NASDAQ:TXG) was provided by Barclays, and 10x Genomics maintained their overweight rating.

When was the last upgrade for 10x Genomics (TXG)?

The last upgrade for 10x Genomics Inc happened on July 22, 2024 when Jefferies raised their price target to $24. Jefferies previously had a hold for 10x Genomics Inc.

When was the last downgrade for 10x Genomics (TXG)?

The last downgrade for 10x Genomics Inc happened on December 11, 2025 when Citigroup changed their price target from N/A to $18 for 10x Genomics Inc.

When is the next analyst rating going to be posted or updated for 10x Genomics (TXG)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 10x Genomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 10x Genomics was filed on December 15, 2025 so you should expect the next rating to be made available sometime around December 15, 2026.

Is the Analyst Rating 10x Genomics (TXG) correct?

While ratings are subjective and will change, the latest 10x Genomics (TXG) rating was a maintained with a price target of $17.00 to $22.00. The current price 10x Genomics (TXG) is trading at is $15.51, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.